Vir Biotechnology (NASDAQ:VIR – Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.
Institutional & Insider Ownership
65.3% of Vir Biotechnology shares are held by institutional investors. 15.6% of Vir Biotechnology shares are held by insiders. Comparatively, 15.8% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Vir Biotechnology and Kymera Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vir Biotechnology | 0 | 2 | 3 | 0 | 2.60 |
| Kymera Therapeutics | 0 | 4 | 13 | 1 | 2.83 |
Risk & Volatility
Vir Biotechnology has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.
Valuation and Earnings
This table compares Vir Biotechnology and Kymera Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vir Biotechnology | $62.04 million | 16.43 | -$615.06 million | ($3.92) | -1.89 |
| Kymera Therapeutics | $78.59 million | 34.63 | -$146.96 million | ($2.34) | -17.96 |
Kymera Therapeutics has higher revenue and earnings than Vir Biotechnology. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Vir Biotechnology and Kymera Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vir Biotechnology | -678.40% | -36.71% | -31.00% |
| Kymera Therapeutics | -191.26% | -24.96% | -20.27% |
Summary
Kymera Therapeutics beats Vir Biotechnology on 12 of the 15 factors compared between the two stocks.
About Vir Biotechnology
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
About Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
